Medicinal cannabis patents granted


Both Zelda Therapeutics (ASX: ZLD) and US company JC Pharma Inc have been granted patents for their novel medicinal cannabis technologies.

Zelda’s patent, entitled “prognostic method and kits useful in said method” details a method their method for detecting levels of expression of a novel receptor complex containing HER2 and CB2. This follows their recent announcement on uncovering a treatment pathway for HER2+ breast cancer.

HER2 is a marker of aggresive breast cancer HER2+ while CB2 is a receptor in the endocannabinoid system, which together form a receptor complex representing a prognostic marker for HER2+ breast cancer.

Zelda’s Manging Director, Dr Richard Hopkins said, “We’re derlighted with the allowance of this patent, which supports Zelda’s strategy of building a world-class intellectual property portfolio and the development of cannabis-based products. Furhter news is expected as this patent family progresses through the international examination phase.

On 5 March, JC Pharma Inc announced they have been awarded a US Patent entitled “method and composition for acute treatment of seizures”. The patent covers their intranasal cannabis-based formulation used to terminate ongoing seizure activity in epilepsy and self-injurious behaviour in autistic children.

JC Pharma is a Colorado based company that was founded in 2017 by Jason Cranford, who has been working in the cannabis industry in USA for 25 years. Over the last decade, he has been working on developing a strain of high-CBD hemp to help treat seizures in the order of seconds to minutes, and calm children on the autism spectrum.

Mr Cranford comment, “I knew I had something extraordinary when I heard back from parent caregivers of kids with intractable epilepsy who said our nasal spray stopped seizures faster than anything they had tried before. These families had tried every pharmaceutical FDA approved drug and nothing else worked and the side effects were unbearable. I knew at that moment that we made a good decision to protect the formulation with a patent application so that we could keep it available and affordable for all those who need it.”

With this patent, JC Pharma is following in the footsteps of GW Pharmaceuticals and their pioneering FDA approved cannabis-derived drug, Epidiolex.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blaise Bratter
Blaise Bratter is the Chief Contributor to CannabisIntel. Being involved in the Australian cannabis industry since legalisation in 2016, he is now Operations Manager for ASX listed company MGC Pharmaceuticals.

Get all the latest content delivered straight to your inbox.”